Overview

Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate

Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
This is a double-blind, randomized, cross-over study conducted at centers within the United States. The study consists of five periods: an up to two-week Screening Period, a 5-week Run-In Period, two eight-week study treatment periods and a two-week Washout Period. Patients are assigned randomly (1:1) to one of two treatment sequences: sevelamer carbonate for eight weeks followed by sevelamer hydrochloride for eight weeks or sevelamer hydrochloride for eight weeks followed by sevelamer carbonate for eight weeks
Phase:
Phase 2
Details
Lead Sponsor:
Genzyme, a Sanofi Company
Treatments:
Sevelamer